DBI pseudogene 1 (DBIP1)

DBI pseudogene 1 (DBIP1) is a **processed pseudogene** of the diazepam binding inhibitor (DBI/ACBP) gene family. It contains features typical of pseudogenes, such as lack of introns, sequence insertions/deletions, and absence of known protein-coding or regulatory function. DBIP1 does not produce functional protein product nor is it involved in known therapeutic mechanisms or disease biology[1][3]. Pseudogenes like **DBIP1** originate from functional parent genes (here, DBI/ACBP), usually via retrotransposition, but acquire disabling mutations, do not code for active proteins, and are not direct drug targets[1][3]. The canonical functional gene, **DBI (diazepam binding inhibitor)**, has known biological roles and disease links, but **DBIP1** does not share these roles and is considered non-functional[2][3]. There is no evidence that DBIP1 is a therapeutic/research target or has any associated biomarkers, safety concerns, or relevant drug interactions. Note on terminology and errors: The entry is *misspecified as a potential therapeutic target*. DBIP1 is a pseudogene, not a receptor, enzyme, transporter, or other actionable biological target. It is not involved in biological processes or human disease as an active entity. If you intended to retrieve information about **DBI (diazepam binding inhibitor, ACBP)**, which is a bona fide protein/potential target, please clarify. This entry is solely for the non-functional pseudogene DBIP1[1][2][3].

Other names

DBI Pseudogene 1DBI pseudogeneDBI(psi)DBIP1